(E)-N-methyl-2-(2-oxo-2-phenylethylidene)hydrazinecarbothioamide for COVID-19
c19early.org
COVID-19 Treatment Clinical Evidence
COVID-19 involves the interplay of 400+ viral and host proteins and factors, providing many therapeutic targets.
c19early analyzes 6,000+ studies for 210+ treatments—over 17 million hours of research.
Only three high-profit early treatments are approved in the US.
In reality, many treatments reduce risk,
with 25 low-cost treatments approved across 163 countries.
-
Naso/
oropharyngeal treatment Effective Treatment directly to the primary source of initial infection. -
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
-
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
-
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
-
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
-
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
-
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
-
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
-
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.
(E)-N-methyl-2-(2-oxo-2-phenylethylidene)hydrazinecarbothioamide may be beneficial for
COVID-19 according to the study below.
COVID-19 involves the interplay of 400+ viral and host proteins and factors providing many therapeutic targets.
Scientists have proposed 11,000+ potential treatments.
c19early.org analyzes
210+ treatments.
We have not reviewed (E)-N-methyl-2-(2-oxo-2-phenylethylidene)hydrazinecarbothioamide in detail.
, Design, synthesis, crystal structure of novel hydrazone analogues as SARS-CoV-2 potent inhibitors: MD simulations, MM-GBSA, docking and ADMET studies, Royal Society Open Science, doi:10.1098/rsos.250373
In this study, we have synthesized novel thiohydrazone 3(a–b) and hydrazone analogues 3(c) by one-pot methodology with good to excellent yields (85%–91%). In silico molecular dynamics (MD) simulations, docking, and absorption, distribution, metabolism, excretion and toxicity (ADMET) were evaluated as inhibitor activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (PDB ID: 5N5O) main protease. The dynamics simulations studies and docking were conducted by GROMACS and AutoDock Vina. The ADMET studies of all the compounds were evaluated to understand drug-likeness and potential for therapeutic applications. All the synthesized compounds 3(a–c) exhibited strong docking scores between −5.0 and −5.4 kcal mol −1 to the targeted protein. MD simulations revealed that the 3b protein–ligand complex demonstrated conformational stability throughout most of the 70 ns simulation period with root mean square deviation (RMSD) fluctuations below 3 Å. ADMET predictions indicated that all compounds possessed high gastrointestinal absorption, suggesting good oral bioavailability. By slow evaporation technique, crystals of compound 3b were grown using ethanol and its single crystal X-ray diffraction analysis disclosed that it crystallized in the monoclinic (P2 1 /c) crystal system. Crystal data outlined crystal packing, bond lengths, bond angles, intermolecular hydrogen bonding parameters, etc. This study offers further avenues in the discovery of novel and promising hydrazone analogues against SARS-CoV-2 main protease.